Biotech News

Ensysce Biosciences Reports First Quarter 2026 Financial Results

Ensysce Biosciences (ENSC)Ensysce Biosciences2026-05-15 20:15 ESTEarnings

ENSC (ENSC) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is ensc.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Ensysce Biosciences

Complex-Pain Therapeutics Ensysce Biosciences develops neuroplastogenic and opioid-based therapies for severe and complex pain. The company expanded its strategy through the acquisition of Cy Biopharma. CY200 CY200 is an orphan-designated neuroplastogenic candidate for complex regional pain syndrome type 1. It is designed to address the...

Recent company news

ENSCEnsysce Biosciences2026-08-13 20:15 EST

Stock data

Close: 0.38 USD
Market cap: 3.84M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Ensysce Biosciences Reports First Quarter 2026 Financial Results

Related news

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results

Ensysce Biosciences

Recent company news

Ensysce Biosciences Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Ensysce Biosciences Announces Acquisition of Cy Biopharma and up to $77 Million Private Financing

Ensysce Biosciences Awarded $5.3 Million Installment in NIDA Funding Completing Multi-Year $15 Million Federal Grant

Ensysce Biosciences Enrolls First Patient in Final Phase of PF614-MPAR-102 Clinical Study

Ensysce Biosciences Reports First Quarter 2026 Financial Results

Stock data